Thomas Seoh

Thomas Seoh, columnist, is CEO of Kinexum, a strategic advisory firm providing guidance on regulatory, clinical and other translational matters for life science product development. Previously, he held senior leadership positions in public and private pharmaceutical, biotech and medical device companies for over 25 years, including legal management in the ICN Pharmaceuticals group, General Counsel, then SVP Corporate and Commercial Development, for NASDAQ-listed Guilford Pharmaceuticals (GLIADEL® Wafer for glioblastoma multiforme, propofol pro-drug LUSEDRA ® for conscious sedation and compounds for Parkinson’s disease), CEO of venture-backed Faust Pharmaceuticals in Strasbourg, France (compounds for Parkinson’s disease and Duchenne Muscular Dystrophy), President of NexGen Medical Systems (a novel mechanical thrombectomy device for DVT and stroke) and CEO of Eqalix, (a plant-based skin substitute wound dressing). Thomas holds an AB in Philosophy and History and a JD from Harvard University.